.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,469,012

« Back to Dashboard

Claims for Patent: 6,469,012

Title: Pyrazolopyrimidinones for the treatment of impotence
Abstract:The use of a compound of formula (I) ##STR1## wherein R.sup.1 is H; C.sub.1 -C.sub.3 alkyl; C.sub.1 -C.sub.3 perfluoroalkyl; or C.sub.3 -C.sub.5 cycloalkyl; R.sup.2 is H; optionally substituted C.sub.1 -C.sub.6 alkyl; C.sub.1 -C.sub.3 perfluoroalkyl; or C.sub.3 -C.sub.6 cycloalkyl; R.sup.3 is optionally substituted C.sub.1 -C.sub.6 alkyl; C.sub.1 -C.sub.6 perfluoroalkyl; C.sub.3 -C.sub.5 cycloalkyl; C.sub.3 -C.sub.6 alkenyl; or C.sub.3 -C.sub.6 alkynyl; R.sup.4 is optionally substituted C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkanoyl, (hydroxy)C.sub.2 -C.sub.4 alkyl or (C.sub.2 -C.sub.3 alkoxy)C.sub.1 -C.sub.2 alkyl; CONR.sup.5 R.sup.6 ; CO.sub.2 R.sup.7 ; halo; NR.sup.5 R.sup.6 ; NHSO.sub.2 NR.sup.5 R.sup.6 ; NHSO.sub.2 R.sup.8 ; SO.sub.2 NR.sup.9 R.sup.10 ; or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl; R.sup.5 and R.sup.6 are each independently H or C.sub.1 -C.sub.4 alkyl, or together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino, 4-N(R.sup.11)-piperazinyl or imidazolyl group; R.sup.7 is H or C.sub.1 -C.sub.4 alkyl; R.sup.8 is optionally substituted C.sub.1 -C.sub.3 alkyl; R.sup.9 and R.sup.10 together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino or 4-N(R.sup.12)-piperazinyl group; R.sup.11 is H; optionally substituted C.sub.1 -C.sub.3 alkyl; (hydroxy)C.sub.2 -C.sub.3 alkyl; or C.sub.1 -C.sub.4 alkanoyl; R.sup.12 is H; optionally substituted C.sub.1 -C.sub.6 alkyl; CONR.sup.13 R.sup.14 ; CSNR.sup.13 R.sup.14 ; or C(NH)NR.sup.13 R.sup.14 ; and R?13? and R.sup.14 are each independently H; C.sub.1 -C.sub.4 alkyl; or substituted C.sub.2 -C.sub.4 alkyl; or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man; a pharmaceutical composition for said treatment; and a method of said treatment of said male animal with said pharmaceutical composition or with said either entity.
Inventor(s): Ellis; Peter (Sandwich, GB), Terrett; Nicholas Kenneth (Sandwich, GB)
Assignee: Pfizer Inc (New York, NY)
Application Number:08/549,792
Patent Claims: 1. A method of treating erectile dysfunction in a male animal, comprising administering to a male animal in need of such treatment an effective amount of a compound of formula (I): ##STR3##

wherein: R.sup.1 is H; C.sub.1 -C.sub.3 alkyl; C.sub.1 -C.sub.3 perfluoroalkyl; or C.sub.3 -C.sub.5 cycloalkyl; R.sup.2 is H; C.sub.1 -C.sub.6 alkyl optionally substituted with C.sub.3 -C.sub.6 cycloalkyl; C.sub.1 -C.sub.3 perfluoroalkyl; or C.sub.3 -C.sub.6 cycloalkyl; R.sup.3 is C.sub.1 -C.sub.6 alkyl optionally substituted with C.sub.3 -C.sub.6 cycloalkyl; C.sub.1 -C.sub.6 perfluoroalkyl; C.sub.3 -C.sub.5 cycloalkyl; C.sub.3 -C.sub.6 alkenyl; or C.sub.3 -C.sub.6 alkynyl; R.sup.4 is C.sub.1 -C.sub.4 alkyl optionally substituted with OH, NR.sup.5 R.sup.6, CN, CONR.sup.5 R.sup.6 or CO.sub.2 R.sup.7 ; C.sub.2 -C.sub.4 alkenyl optionally substituted with CN, CONR.sub.5 R.sup.6 or CO.sub.2 R.sup.7 ; C.sub.2 -C.sub.4 alkanoyl optionally substituted with NR.sup.5 R.sup.6 ; (hydroxy)C.sub.2 -C.sub.4 alkyl optionally substituted with NR.sup.5 R.sup.6 ; (C.sub.2 -C.sub.3 alkoxy)C.sub.1 -C.sub.2 alkyl optionally substituted with OH or NR.sup.5 R.sup.6 ; CONR.sup.5 R.sup.6 ; CO.sub.2 R.sup.7 ; halo; NR.sup.5 R.sup.6 ; NHSO.sub.2 NR.sup.5 R.sup.6 ; NHSO.sub.2 R.sup.8 ; SO.sub.2 NR.sup.9 R.sup.10 ; or phenyl pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl; R.sup.5 and R.sup.6 are each independently H or C.sub.1 -C.sub.4 alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino, 4-N(R.sup.11)-piperazinyl or imidazolyl group wherein said group is optionally substituted with methyl or OH; R.sup.7 is H or C.sub.1 -C.sub.4 alkyl; R.sup.8 is C.sub.1 -C.sub.3 alkyl optionally substituted with NR.sup.5 R.sup.6 ; R.sup.9 and R.sup.10 together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino or 4-N(R.sup.12)-piperazinyl group wherein said group is optionally substituted with C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.3 alkoxy, NR.sup.13 R.sup.14 or CONR.sup.13 R.sup.14 ; R.sup.11 is H; C.sub.1 -C.sub.3 alkyl optionally substituted with phenyl; (hydroxy)C.sub.2 -C.sub.3 alkyl; or C.sub.1 -C.sub.4 alkanoyl; R.sup.12 is H; C.sub.1 -C.sub.6 alkyl; (C.sub.1 -C.sub.3 alkoxy)C.sub.2 -C.sub.6 alkyl; (hydroxy)C.sub.2 -C.sub.6 alkyl; (R.sup.13 R.sup.14 N)C.sub.2 -C.sub.6 alkyl; (R.sup.13 R.sup.14 NOC)C.sub.1 -C.sub.6 alkyl; CONR.sup.13 R.sup.14 ; CSNR.sup.13 R.sup.14 ; or C(NH)NR.sup.13 R.sup.14 ; and R.sup.13 and R.sup.14 are each independently H; C.sub.1 -C.sub.4 alkyl; (C.sub.1 -C.sub.3 alkoxy)C.sub.2 -C.sub.4 alkyl; or (hydroxy)C.sub.2 -C.sub.4 alkyl; or a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable composition containing either entity.

2. A method as defined in claim 1, wherein said treatment is veterinary treatment.

3. A method as defined in claim 1, wherein said compound is 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-p yrazolo[4,3-d]pyrimidin-7-one.

4. A method as defined in claim 1, wherein said compound is 5-[2-ethoxy-5-(4-methyl-1-piperazinyl-sulphonyl)phenyl]-1-methyl-3-n-propy l-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.

5. A method as defined in claim 1, wherein said compound, salt or composition is administered orally, intravenously, sublingually, or buccally.

6. A method as defined in claim 1, wherein said compound, salt or composition is administered orally.

7. A method as defined in claim 6 wherein in the compound of formula (I) R.sup.1 is H, methyl or ethyl; R.sup.2 is C.sub.1 -C.sub.3 alkyl; R.sup.3 is C.sub.2 -C.sub.3 alkyl or allyl; R.sup.4 is C.sub.1 -C.sub.2 alkyl optionally substituted with OH, NR.sup.5 R.sup.6, CN, CONR.sup.5 R.sup.6 or CO.sub.2 R.sup.7 ; acetyl optionally substituted with NR.sup.5 R.sup.6 ; hydroxyethyl optionally substituted with NR.sup.5 R.sup.6 ; ethoxymethyl optionally substituted with OH or NR.sup.5 R.sup.6 ; CH.dbd.CHCN; CH.dbd.CHCONR.sup.5 R.sup.6 ; CH.dbd.CHCO.sub.2 R.sup.7 ; CONR.sup.5 R.sup.6 ; CO.sub.2 H; Br; NR.sup.5 R.sup.6 ; NHSO.sub.2 NR.sup.5 R.sup.6 ; NHSO.sub.2 R.sup.8 ; SO.sub.2 NR.sup.9 R.sup.10 ; or pyridyl or imidazolyl either of which is optionally substituted with methyl; R.sup.5 and R.sup.6 are each independently H, methyl or ethyl, or together with the nitrogen atom to which they are attached form a piperidino, morpholino, 4-N(R.sup.11)-piperazinyl or imidazolyl group wherein said group is optionally substituted with methyl or OH; R.sup.7 is H or t-butyl; R.sup.8 is methyl or CH.sub.2 CH.sub.2 CH.sub.2 NR.sup.5 R.sup.6 ; R.sup.9 and R.sup.10 together with the nitrogen atom to which they are attached form a piperidino or 4-N(R.sup.12)-piperazinyl group wherein said group is optionally substituted with NR.sup.13 R.sup.14 or CONR.sup.13 R.sup.14 ; R.sup.11 is H, methyl, benzyl, 2-hydroxyethyl or acetyl; R.sup.12 is H, C.sub.1 -C.sub.3 alkyl, (hydroxy)C.sub.2 -C.sub.3 alkyl, CSNR.sup.13 R.sup.14 or C(NH)NR.sup.13 R.sup.14 ; and R.sup.13 and R.sup.14 are each independently H or methyl.

8. A method as defined in claim 7 wherein in the compound of formula (I) R.sup.1 is methyl or ethyl; R.sup.2 is C.sub.1 -C.sub.3 alkyl; R.sup.3 is ethyl, n-propyl or allyl; R.sup.4 is CH.sub.2 NR.sup.5 R.sup.6, COCH.sub.2 NR.sup.5 R.sup.6, CH(OH)CH.sub.2 NR.sup.5 R.sup.6, CH.sub.2 OCH.sub.2 CH.sub.3, CH.sub.2 OCH.sub.2 CH.sub.2 OH, CH.sub.2 OCH.sub.2 CH.sub.2 NR.sup.5 R.sup.6, CH.dbd.CHCON(CH.sub.3).sub.2, CH.dbd.CHCO.sub.2 R.sup.7, CONR.sup.5 R.sup.6, CO.sub.2 H, Br, NHSO.sub.2 NR.sup.5 R.sup.6, NHSO.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 NR.sup.5 R.sup.6, SO.sub.2 NR.sup.9 R.sup.10, 2-pyridyl, 1-imidazolyl or 1-methyl-2-imidazolyl; R.sup.5 and R.sup.6 together with the nitrogen atom to which they are attached form a piperidino, 4-hydroxypiperidino, morpholino, 4-N(R.sup.11)-piperazinyl or 2-methyl-1-imidazolyl group; R.sup.7 is H or t-butyl; R.sup.9 and R.sup.10 together with the nitrogen atom to which they are attached form a 4-carbamoylpiperidino or 4-N(R.sup.12)-piperazinyl group; R.sup.11 is H, methyl, benzyl, 2-hydroxyethyl or acetyl; and R.sup.12 is H, C.sub.1 -C.sub.3 alkyl, 2-hydroxyethyl or CSNH.sub.2.

9. A method as defined in claim 8 wherein in the compound of formula (I) R.sup.1 is methyl or ethyl; R.sup.2 is n-propyl; R.sup.3 is ethyl, n-propyl or allyl; R.sup.4 is COCH.sub.2 NR.sup.5 R.sup.6, CONR.sup.5 R.sup.6, SO.sub.2 NR.sup.9 R.sup.10 or 1-methyl-2-imidazolyl; R.sup.5 and R.sup.6 together with the nitrogen atom to which they are attached form a morpholino or 4-N(R.sup.11)-piperazinyl group; R.sup.9 and R.sup.10 together with the nitrogen atom to which they are attached form a 4-N(R.sup.12)-piperazinyl group; R.sup.11 is methyl or acetyl; and R.sup.12 is H, methyl, 2-propyl or 2-hydroxyethyl.

10. A method as defined in claim 9 wherein the compound of formula (I) is selected from: 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-py razolo[4,3-d]pyrimidin-7-one; 5-(5-morpholinoacetyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H -pyrazolo[4,3-d]pyrimidin-7-one; 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)-phenyl]-1-methyl-3-n-propyl -1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 5-[2-allyloxy-5-(4-methyl-1-piperazinylsulphonyl)-phenyl]-1-methyl-3-n-prop yl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 5-{2-ethoxy-5-[4-(2-propyl)-1-piperazinyl-sulphonyl]phenyl}-1-methyl-3-n-pr opyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 5-{2-ethoxy-5-[4-(2-hydroxyethyl)-1-piperazinyl-sulphonyl]phenyl}-1-methyl- 3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 5-{5-[4-(2-hydroxyethyl)-1-piperazinylsulphonyl]-2-n-propoxyphenyl}-1-methy l-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 5-[2-ethoxy-5-(4-methyl-1-piperazinylcarbonyl)-phenyl]-1-methyl-3-n-propyl- 1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; and 5-[2-ethoxy-5-(1-methyl-2-imidazolyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydr o-7H-pyrazolo[4,3-d]pyrimidin-7-one.

11. A method as defined in claim 10 wherein the compound of formula (I) is 5-(2-ethoxy-5-morpholino-acetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H- pyrazolo[4,3-d]pyrimidin-7-one.

12. A method as defined in claim 10 wherein the compound of formula (I) is 5-(5-morpholinoacetyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7 H-pyrazolo[4,3-d]pyrimidin-7-one.

13. A method as defined in claim 10 wherein the compound of formula (I) is 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)-phenyl]-1-methyl-3-n-propy l-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.

14. A method as defined in claim 10 wherein the compound of formula (I) is 5-[2-allyloxy-5-(4-methyl-1-piperazinylsulphonyl)-phenyl]-1-methyl-3-n-pro pyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.

15. A method as defined in claim 10 wherein the compound of formula (I) is 5-{2-ethoxy-5-[4-(2-propyl)-1-piperazinyl-sulphonyl]phenyl}-1-methyl-3-n-p ropyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.

16. A method as defined in claim 10 wherein the compound of formula (I) is 5-{2-ethoxy-5-[4-(2-hydroxyethyl)-1-piperazinyl-sulphonyl]phenyl}-1-methyl -3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.

17. A method as defined in claim 10 wherein the compound of formula (I) is 5-{5-[4-(2-hydroxyethyl)-1-piperazinylsulphonyl]-2-n-propoxyphenyl}-1-meth yl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.

18. A method as defined in claim 10 wherein the compound of formula (I) is 5-[2-ethoxy-5-(4-methyl-1-piperazinylcarbonyl)-phenyl]-1-methyl-3-n-propyl -1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.

19. A method as defined in claim 10 wherein the compound of formula (I) is 5-[2-ethoxy-5-(1-methyl-2-imidazolyl)phenyl]-1-methyl-3-n-propyl-1,6-dihyd ro-7H-pyrazolo[4,3-d]pyrimidin-7-one.

20. A method as defined in claim 6, wherein said animal is a human.

21. A method as defined in claim 1, wherein said compound, salt or composition is administered intravenously.

22. A method as defined in claim 1, wherein said compound, salt or composition is administered sublingually.

23. A method as defined in claim 1, wherein said compound, salt or composition is administered buccally.

24. A method of treating erectile dysfunction in a male human, comprising orally administering to a male human in need of such treatment an effective amount of a selective cGMP PDE.sub.v inhibitor, or a pharmaceutically acceptable salt thereof, of a pharmaceutical composition containing either entity.

25. A method of treating erectile dysfunction in a male human, comprising orally administering to a male human in need of such treatment an effective amount of a compound selected from: 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-py razolo[4,3-d]pyrimidin-7-one; 5-(5-morpholinoacetyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H -pyrazolo[4,3-d]pyrimidin-7-one; 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)-phenyl]-1-methyl-3-n-propyl -1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 5-[2-allyloxy-5-(4-methyl-1-piperazinylsulphonyl)-phenyl]-1-methyl-3-n-prop yl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 5-{2-ethoxy-5-[4-(2-propyl)-1-piperazinyl-sulphonyl]phenyl}-1-methyl-3-n-pr opyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 5-{2-ethoxy-5-[4-(2-hydroxyethyl)-1-piperazinyl-sulphonyl]phenyl}-1-methyl- 3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 5-{5-[4-(2-hydroxyethyl)-1-piperazinylsulphonyl]-2-n-propoxyphenyl}-1-methy l-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 5-[2-ethoxy-5-(4-methyl-1-piperazinylcarbonyl)-phenyl]-1-methyl-3-n-propyl- 1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; and 5-[2-ethoxy-5-(1-methyl-2-imidazolyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydr o-7H-pyrazolo[4,3-d]pyrimidin-7-one;

or a pharmaceutically acceptable salt thereof;

or a pharmaceutical composition containing either entity.

26. A method as defined in claim 25, wherein said compound is 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)-phenyl]-1-methyl-3-n-propy l-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc